Inhibikase Therapeutics (Inhibikase Therapeutics) EV-to-FCF : -0.14 (As of May. 28, 2024)

Inhibikase Therapeutics EV-to-FCF Chart

Inhibikase Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-FCF	Get a 7-Day Free Trial															0.26	0.08	0.50	0.28	-0.28

Competitive Comparison of Inhibikase Therapeutics's EV-to-FCF

For the Biotechnology subindustry, Inhibikase Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Inhibikase Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inhibikase Therapeutics's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Inhibikase Therapeutics's EV-to-FCF falls into.

Inhibikase Therapeutics EV-to-FCF Calculation

Inhibikase Therapeutics's EV-to-FCF for today is calculated as:

Inhibikase Therapeutics's current Enterprise Value is $2.18 Mil.
Inhibikase Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-15.98 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inhibikase Therapeutics  (NAS:IKT) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Inhibikase Therapeutics's PE Ratio for today is calculated as:

Inhibikase Therapeutics's share price for today is $1.76.
Inhibikase Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.340.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.

Inhibikase Therapeutics EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Inhibikase Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.

Inhibikase Therapeutics (Inhibikase Therapeutics) Business Description